reason report
diseas merit look initi op pt
bottom line initi coverag mereo biopharma
mreo op rate pt believ rare disease-
focus biopharma compani could gain investor interest two
late-stag asset setrusumab alvelestat key near-
term data readout see sever potenti catalyst investor
realiz valu creation start ph asteroid data setrusumab
osteogenesi imperfecta/oi ph astreau data
alvelestat antitrypsin deficiency/aatd
binari catalyst expect pre-commerci biopharma compani
mreo assum posit data materi mreo two
lead product could becom re-defin standard care soc
current approv drug oi setrusumab pois
first anabol therapi market mereo lead candid
setrusumab anti-sclerostin antibodi strong safeti profil
encourag phase asteroid interim data adult type
iv oi data show signific improv trabecular
volumetr bone miner densiti tr vbmd wrist increas
data expect asteroid pediatr pivot trial
slate initi canada diseas consider
unmet medic need safe efficaci setrusumab could becom
prefer bone-build agent oi project
global peak sale risk-adjust probabl success po
highli differenti iv augment therapi soc first-in-
class oral alvelestat could signific disrupt aatd market
alvelestat small molecul inhibitor neutrophil elastas primari
caus lung degrad aatd patient previou phase studi
alvelestat chronic obstruct pulmonari diseas copd cystic
fibrosi bronchiectasi demonstr clean safeti profil show
mix result biomark desmosine/isodesmosin lung function
improv given biolog nuanc indic remain
cautious optimist alvelestat meet biomark primari endpoint
posit top-line ph astreau data anticip could
re-risk alvelestat aatd project global
peak sale risk-adjust po
estim core strategi focus rare diseas
mereo plan out-licens non-rar diseas asset acumapimod
leflutrozol oncolog product navicixizumab etigilimab prior
commerci project revenu program
junctur potenti offer import sourc non-dilut
capit concurr seek partnership non-rar diseas asset
mereo also activ look expand diversifi rare diseas portfolio
acquir addt product major pharma compani lt growth
dcf discount rate
net debt total capit
year price history/av daili volume mil mreo
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
diseas merit look initi op pt
mereo mreo biopharma compani focus develop
commerci rare diseas therapi area bone respiratori endocrin
diseas pend posit data mereo agent could becom re-defin standard care
soc target indic mereo lead candid
anti-sclerostin antibodi strong safeti profil aim treat mild moder
osteogenesi imperfecta oi also known brittl bone diseas current
approv drug oi setrusumab pois first anabol therapi market oi
diseas consider unmet medic need safe efficaci setrusumab
could becom prefer bone-build agent pt oi mereo second shot
goal oral small molecul treatment antitrypsin
defici aatd highli differenti iv augment therapi soc first-in-class
oral alvelestat could signific disrupt aatd market alvelestat patient-
friendli small molecul inhibitor neutrophil elastas primari caus lung
degrad aatd patient could come re-defin soc addit mereo
pipelin includ four non-rar diseas asset
core strategi focus rare diseas mereo plan out-licens
addit non-rar diseas oncolog product prior commerci offer
addit upsid current estim mereo share began trade april
revers merger oncom ome whose ticker
replac mreo expect multipl near-term catalyst put under-the-radar
biopharma compani map
deriv one-year pt mreo base dcf
analysi use discount rate termin
current ascrib valu compani two rare diseas
asset setrusumab alvelestat
 setrusumab assign probabl success
po osteogenesi imperfect oi project peak
sale
 alvelestat assign probabl success po
antitrypsin defici aatd project peak
sale
meanwhil ascrib valu non-rar
diseas asset
manag intend
repres ad upsid estim
compani file svb leerink research estim gbp exchang rate base year date averag
mreo risk valuat
clinical-stag compani risk mreo includ clinic regulatori financi
 lead asset setrusumab add signific binari risk head data readout
 full safeti profil setrusumab includ long-term use remain unknown
 clinic risk associ clinic candid alvelestat
 commerci uptak sale
market close
compani focus develop commerci rare diseas therapi area bone respiratori
endocrin diseas pend posit data mreo agent could becom re-defin standard care soc
 lead product candid setrusumab human monoclon antibodi posit first approv
anabol agent treatment osteogenesi imperfecta oi
 second program alvelestat treatment trypsin defici aatd potenti
transform current soc
recent success bone bmrn op vimizim rare op crysvita alxn op strensiq cmta/ipsen
palovaroten respiratori insm op arikayc rhhbi esbriet atln uptravi vrtx mp symdeko
core strategi focus rare diseas mereo plan out-licens addit non-rar diseas oncolog
product prior commerci offer addit upsid
april merger increas mreo cash oper runway
inflect point top product candid expect
mreo glanc invest highlight
aim improv bone strength
inhibit neutrophil elastas activ
primari caus aatd lung degrad
potenti first approv drug oi
potenti re-defin soc aatd
opportun peak
opportun peak
mereo biopharma rich near-term success-defin catalyst
bull vs bear argument mereo biopharma
mreo divers indic asset portfolio
allow multipl independ rout market
runway expect fund oper mid-
multipl value-cr catalyst
setrusumab pois first approv anabol
agent treatment oi
alvelestat patient-friendli oral highli
differenti soc iv augment therapi
experienc bd team proven transact
track record plan continu expand rare-
diseas pipelin larg pharma acquisit
setrusumab act bone-build agent oi
bisphosphon denosumab
phase data adult success oi
although cv safeti signal report
setrusumab anti-sclerostin antibodi
alvelestat address underli diseas
presum effect liver manifest
aatd grossli underdiagnos may hinder
albeit indic alvelestat show mix
data previou phase trial
mereo multipl late-stag asset potenti valu creation
acut exacerb copd
hypogonad obes men
phase readi canada
phase safeti extens complet
setrusumab
project peak revenu opportun setrusumab oi
mreo intend address broad oi popul rang mild type sever type target
popul could us eu
current approv treatment oi bisphosphon commonli prescrib off-label
rather view competit howev anti-resorpt bisphosphon could
administ combin sequenc setrusumab ad clinic benefit
believ anti-sclerostin antibodi re-disk osteoporosi project peak penetr
setrusumab amgn even shown mark bone improv osteoporosi pt
harbor black box warn approv treatment oi setrusumab share similar
mechan action moa could benefit anti-sclerostin familiar
setrusumab price assumpt us/eu conserv consid
crysvita price tag recent fda approv medic anoth rare bone disord x-link
hypophosphatemia/xlh rare crysvita clock annual price children
setrusumab osteogenesi imperfecta oi background
osteogenesi imperfecta oi also known brittl bone diseas
 genet chronic bone disord character fragil bone fractur easili
bone scoliosi short statur also common
inhibit sclerostin human monoclon antibodi
 sclerostin glycoprotein express bone cell respond mechan stress
play vital role inhibit osteoblast bone format
case link mutat one two gene encod type collagen
key compon healthi bone
date fda ema approv treatment oi
 soc current aim mitig symptom includ physic therapi fractur care orthoped
surgeri mobil equip medic strengthen bone
medic off-label use osteoporosi medic bisphosphon denosumab
adult phase asteroid top-line data expect
pediatr pivot registr studi canada expect initi
current soc oi rang mild sever entail fractur
manag off-label use osteoporosi medic
common
type
rel fractur
mild moder bone
shorter averag
surviv
light-blu normal
normal near-norm
glorieux guid oi pediatrician famili practic physician nih osteogenesi imperfecta foundat medacorp svb leerink research
birth shortli
due respiratori
small statur
report
well mild type oi
pt under-perform
mani
oi patient suffer brittl bone fractur easili anabol
agent anti-resorpt aim increas bone miner densiti bmd
format new
miner
mreo compani present tanaka eor openstax anatomi physiolog svb leerink research
sclerostin antibodi aim
increas bone densiti oi
patient lift sclerostin
inhibit osteoblast
differenti bone
use sequenti anabol anti-resorpt agent increas
osteoporosi pt treat anti-
even year demonstr
lumbar spine bmd gain similar pt
year denosumab prolia
addit pt treat even
follow prolia achiev bmd
gain compar pt treat sole
prolia year
result suggest clinic benefit
rebuild skelet foundat
anabol therapi transit
anti-resorpt agent
rather view
competit anti-resorpt
prolia bisphosphon could
administ combin
sequenc setrusumab
studi osteoporosi pt suggest clinic benefit
treatment anabol bone-build
agent anti-resorpt medic block
breakdown bone
approv drug oi mreo setrusumab posit
first bone-build therapi market
cancer
osteoporosi
osteoporosi postmenopaus women
osteoporosi postmenopaus women
soc often includ off-label use bisphosphon
shown increas bmd fail show consist improv fractur rate clinic statu
reduc pain improv mobil
lli forteo carri black box warn increas bone cancer risk
amgn even harbor black box warn cv issu
lli blosozumab suffer formul issu
phase studi setrusumab stimul bone format
reduc bone resorpt biomark adult oi patient
primari endpoint success met chang biomark baselin
substanti increas pt
treat setrusumab day
pinp
picp
bsap
oc
decreas setrusumab pt day
similar respons report
anti-sclerostin antibodi
treatment postmenopaus
dual mechan setrusumab
oi patient
on-going phase asteroid studi data expect read
open label arm top dose
report
trabecular volumetr bmd tr vbmd hr-pqct vs baselin
chang bone strength use finit element analysi fea
tr bmd hr-pqct month
bmd dxa scan month
qualiti life
blind arm
posit data phase asteroid open-label arm show
notabl increas end point measur tr vbmd radiu
hrpqct scan oi patient vs control baselin
posit data open-label high-dos patient moder oi type iv
substanti increas trabecular volumetr bone miner densiti tr vbmd vs baselin radiu
month
month
markedli greater radial bmd increas report oi patient treat teriparatid
month osteoporosi patient denosumab month
trabecular spongi bone provid intern bone strength main load bear bone type lattice-lik
network allow shock absorpt decreas oi pt contribut increas fractur rate
setrusumab well toler dose
report seriou advers event sae cardiovascular signal seen previous amgn even
common ae headach
mreo compani present websit tsai et al jbmr orwol et al clin invest svb leerink research
phase asteroid studi result competit lumbar spine
abmd improv seen osteoporot agent oi patient
setrusumab month
treatment setrusumab increas lumbar spine abmd baselin month oi pt
similar abmd increas seen setrusumab treatment hypophosphatasia month
trend toward increas demonstr anti-sclerostin antibodi osteoporosi
lli blosozumab amgn even
top-line data three blind arm expect
pediatr pivot registr studi setrusumab oi slate initi
 canada
random placebo select
 canada
fractur rate vs placebo month
tr bmd hr-pqct month
bmd dxa scan month
qualiti life
mereo compani present websit svb leerink research
initi
 canada
setrusumab oi benchmark pediatr pivot registr trial
primari endpoint fractur rate vs placebo month
anti-resorpt bisphosphon fail demonstr consist deduct fractur rate
statist signific decreas fractur rate setrusumab would clinic meaning
month
month
month
signific
least
secondari endpoint chang lumbar abmd
anti-resorpt agent averag increas
lumbar spine abmd month
compar greater increas abmd would
bode well mreo
mean chang baselin lumbar spine
abmd month
patient-cent physician-cent
point view fractur reduct
grant orphan statu
phase studi design agre ema
grant prioriti medicin prime statu includ
adapt pathway
engag fda initi pediatr phase
trial
mereo compani present websit gatti et al jbmr ward et al jcem bishop et al lancet hoyer-kuhn et al musculoskelet neuron interact medacorp svb leerink research
linger uncertainti oi pediatr pivot registr trial
base previou oi pediatr studi data remain uncertain setrusumab success
meet primari endpoint fractur rate deduct
controversi field still unclear bisphosphon significantli decreas fractur
rate pediatr oi pt
bmd measur appear common primari endpoint pediatr oi trial
demonstr robust consist improv across agent trial
howev anti-sclerostin antibodi amgn even lli blosozumab
shown signific reduct fractur rate osteoporosi patient translat
pediatr oi patient popul yet seen
date avail setrusumab data oi patient adult popul
adult oi clinic data map younger patient unknown
mreo plan engag fda align discuss year end pediatr
pivot trial initi date tbd
alvelestat
project peak revenu opportun alvelestat aatd
aatd patient current iv augment therapi us oral administr alvelestat
offer conveni option patient may increas number aatd pt seek treatment
histor under- mis-diagnos model modest treatabl patient popul
possibl pi zz null aatd patient us eu accord estim
often seen rare diseas drug launch diseas awar could drive addit diagnosi
potenti increas treatabl patient popul
project conserv commerci uptak peak penetr alvelestat soc
chang year uncertain quickli doctor adopt new therapeut approach howev
alvelestat conveni formul patient-friendli oral could help commerci uptak
alvelestat price assumpt us/eu competit yearli
cost iv augment therapi rang
alvelestat antitrypsin defici aatd
 genet disord caus increas risk earli onset pulmonari diseas liver
diseas skin problem inflamm blood vessel
caus mutat gene encod protein
inhibitor neutrophil elastas
 restor inhibit lost due low antitrypsin protein present lung
estim preval homozyg pi zz null
 individu world-wide
 grossli under- misdiagnos
current soc includ weekli augment therapi iv-infus antitrypsin
 inhal supplement oxygen may also need
 augment therapi affect liver diseas associ aatd
thu addit medic lactulos may need
mereo compani present websit bianco et al chron obstruct pulmon stoller aboussouan ajrccm svb leerink research
defici predispos patient chronic obstruct pulmonari
diseas copd liver diseas
protect lung
degrad
liver synthes
releas
defici lead
increas ne activ
build abnorm
fold lead
mutat gene lead misfold protein pi zz mutat complet lack
lung defici leav proteolyt neutrophil elastas ne uncheck caus increas elastin
degrad risk early-onset pulmonari emphysema
liver aggreg misfold caus jaundic cirrhosi hepatocellular carcinoma
pi zz pt lung liver effect lack pi nullnul pt spare aggreg
liver pulmonari issu remain
current soc includ augment therapi weekli iv infus purifi pool human plasma
foundat stoller aboussousan ajrccm brantley et al chronic obstr pulm di freepik com svb leerink research
soc chang decad aatd competit
landscap open innov
rnai knockdown
rnai knockdown sc
rnai knockdown sc
unlik investig agent mreo first-in-class alvelestat
specif target primari caus lung degrad aatd patient
liver
increas ne
activ lung
highli differenti protein replac therapi mreo oral alvelestat pois redefin soc
iv augment therapi costli per year inconveni
alvelestat oral administr elimin need weekli clinic visit infusion-associ risk
rnai therapi address aatd-associ liver diseas pulmonari manifest
vrtx corrector molecul could theori improv liver lung outcom
clinic data report date
gene therapi address underli diseas hold promis commerci long
upcom phase astraeu studi data posit could
de-risk alvelestat aatd
pizz null
within-individu chang biomark vs baselin week
addit blood biomark ne activ
chang baselin st georg
chang baselin pulmonari function
forc expiratori volum second
mereo compani present websit clincialtri gov svb leerink research
desmosin reduct cystic fibrosi pt respiratori diseas
reduct urinari desmosin cystic
elastin cleavag neutrophil elastas ne
confirm alvelestat moa inhibit ne
cf like aatd respiratori diseas
character neutrophil inflamm
decreas urinari desmosin
treat alvelestat day
although signific reduct desmosin
plasma level cf pt also report
support alvelestat moa
chang
baselin
signific
signific
correl lung function measur desmosine/isodesmosin
valid biomark endogen elastin degrad aatd pt
releas desmosin de
elastin
desmosin de isodesmosin
cross-link uniqu matur elastin fiber
destruct elastin neutrophil elastas ne
lead releas de increas
urinari plasma excret
des/id plasma level aatd pt baselin
month
plasma level correl slower declin lung
densiti month
trial serv import templat
understand relationship
biomark lung function aatd pt
consist csl trial find alvelestat demonstr lung
function improv addit phase trial
bronchiectasi pt treat alvelestat show increas mean valu lung function
test fvc day wherea placebo group decreas measur
bronchiectasi like aatd respiratori diseas neutrophil inflamm
alvelestat-tr pt show signific increas ml forc expiratori
volum second
result suggest alvelestat may improv lung function aatd pt
remain uncertainti alvelestat aatd
although safe well toler across indic trial alvelestat fail consist
decreas desmosin level improv lung function respiratori diseas
albeit indic mix result alvelestat chronic obstruct pulmonari
diseas copd cystic fibrosi bronchiectasi add uncertainti aatd phase
well-
non-rar diseas asset potenti offer import sourc non-dilut
chronic obstruct
lung function day
reduct
rehospit
copd day
hypogonad hh
increas testosteron
inhibit convers
demonstr increas
testosteron lh fsh
expect exhibit
anti-angiogen anti-
phase combin
paclitaxel on-going
patient
advanc metastat
expect prevent t-cell
attack tumor cell
similar
agent activ phase
combin
well toler
well toler
fda announc
mereo compani present websit svb leerink research
manag team combin strong transact experi rare
denis scots-knight ph ceo co-found
ceo board member sinc co-found compani juli
year experi biopharmaceut industri manag life scienc invest includ
serv manag partner partner
ph univers birmingham fulbright scholar uc berkeley
alastair mackinnon mbb co-found
sinc co-found compani juli
year practic physician uk
bsc mbb king colleg london member royal colleg surgeon edinburgh corpor
financ diploma holder london busi school
cfo board member sinc
join mereo shield therapeut plc serv cfo compani secretari
extens financi experi healthcar invest bank hold senior posit investec brewin dolphin
john richard head corpor develop co-found
head corpor develop sinc co-found compani
signific corpor oper transact experi includ serv execut vice-president busi develop
sequu pharmaceut
mba harvard busi school bs stanford univers
will hughes-wilson head patient access commerci plan
head patient access commerci plan sinc
expertis extens experi rare orphan diseas product commerci vice-president health market
access polici genzym corpor
recent serv chief patient access offic swedish orphan biovitrum sobi
strong ip protect across product portfolio mid-to-l
antibodi use grant major territori
data market exclus europ
compound per se major territori
data market exclus
novel salt/polymorph grant major territori
formul medic use grant major territori
data market exclus
compound per se major territori
data market exclus
medic use grant major territori
antibodi use grant major territori
data market exclus europ
medic use granted/pend major territori
antibodi use grant major territori
data market exclus europ
medic use granted/pend major territori
mreo compani present websit svb leerink research depend date
increas influenc advocaci group could facilit drug
develop oi aatd
conclus setrusumab pois becom first-approv bone-build
agent oi first-in-class alvelestat seek redefin soc aatd
current approv drug oi setrusumab pois first bone-build therapi
market
favor safeti profil setrusumab increas optim project use off-label
anabol agent signific safeti risk
posit interim data phase asteroid trial bode well setrusumab efficaci
oi
pend posit data oral alvelestat could signific disrupt current augment
near-term data catalyst rare diseas program
non-rar diseas asset potenti offer sourc non-dilut financ addit upsid
estim
season manag team notabl transact experi activ look build rare
diseas pipelin acquisit big-pharma data-back asset long-term growth
project peak revenu opportun setrusumab oi
osteogenesi imperfecta revenu model mm us pop us annual pop growth us total oi popul type type iii/iv oi treatabl patient setrusumab penetr treat patients- setrusumab price annual price increas sale mm us sale mm us eu revenu model mm eu pop eu annual pop growth eu total oi popul type type iii/iv oi treatabl patient setrusumab penetr treat patients- setrusumab price annual price increas sale mm eu sale mm eu ww gross sale mm eu ww sale mm eu assumptionssetrusumab price setrusumab price price increas increas success po success po mreo biopharma us censu bureau world bank group svb leerink research mereo biopharma group plc
project peak revenu opportun alvelestat aatd
antitrypsin defici revenu model mm us pop us annual pop growth us total pizz null aatd popul treatabl patient alvelestat penetr alvelestat- alvelestat price annual price increas sale mm us sale mm us eu revenu model mm eu pop eu annual pop growth eu total pizz null aatd popul treatabl patient alvelestat penetr alvelestat- alvelestat price annual price increas sale mm eu sale mm eu ww gross sale mm eu ww sale mm eu royal rate payment azn- assumptionsalvelestat price alvelestat price price increas increas success po success po pizz pizz mreo biopharma us censu bureau world bank group svb leerink research mereo biopharma group plc
net incom recognis aquisit subsidiari
equival
chang cash gbp mm
